Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Advanced Proteome Therapeutics Corporation (V:APC)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for APC within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 14, 2018 08:30 ET
Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma
Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging...
Read full article
Oct 15, 2018 08:30 ET
Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals
Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.28
--
--
Price to Sales - TTM
--
16.69
10.56
Price to Book - most recent quarter
1.83
3.16
2.07
Price to Cash Flow per share - TTM
--
31.32
12.29
Price to Free Cash Flow per share - TTM
--
1.27
18.54
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 31, 202010,0000
Nov 15, 201918,0000
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Advanced Proteome Therapeutics Corporation is a biotechnology company. The Company is engaged in the development of anti-cancer therapeutics that exploit the properties of a natural human protein. The Company, through its subsidiary, Advanced Proteome Therapeutics Inc. (APTI), develops and commercializes a new technology platform that is intended for the chemical modification of protein therapeutics. The Foundation Trinity Technology is combining anti-cancer therapies in a single agent for targeted delivery to tumors. It is engaged in targeted therapy, immunotherapy and combination therapy. The Company's technology is applicable to the areas of therapeutics and diagnostics, protein drugs and personalized medicine, and is being applied to cancer therapeutics. It is focusing on enabling technology, designed to link antibodies to drugs or toxins, to produce pure and homogeneous antibody-drug conjugates (ADC).

See business summary

Twitter

Search (past week) for $APC.CA APC.V

  • No tweets found